Company: WSBC
Filing Date: 2025-09-11
Form Type: 424B5
Source: 0001193125-25-201360
Chunk: 70

Company: WESBANCO INC
Filing Date: 2025-09-11
Form: 424B5
Chunk 70
---
                                  |     | Per        
 Depositary 
 Share      |         |     | Total |             |
|:---------------------------------|:----|:-----------|--------:|:----|:------|------------:|
| Public offering price(1)         |     | $          |   25.00 |     | $     | 230,000,000 |
| Underwriting discount(2)         |     | $          |  0.5343 |     | $     |   4,915,675 |
| Proceeds, before expenses, to us |     | $          | 24.4657 |     | $     | 225,084,325 |

S-48

| (1) | Plus accrued dividends, if any, from to the original issuance date. |

| (2) | Reflects 8,102,000 depository shares sold to institutional investors, for which the underwriters received an                                                                                                   
 underwriting discount of $0.5000 per depository share, and 1,098,000 depository shares sold to retail investors, for which the underwriters received an underwriting discount of $0.7875 per depository share. |

The expenses of the offering, not including the underwriting discount, are estimated at $1,100,000 and are payable by us. Nasdaq Global Select Market Listing Prior to this offering, there has been no public market for the depositary shares. We do not expect that there will be any separate public trading market for the shares of the Series B Preferred Stock except as represented by the depositary shares. We intend to apply to list the depositary shares on the Nasdaq Global Select Market under the symbol “WSBCPB.” If the application is approved, we expect trading of the depositary shares on the Nasdaq Global Select Market to begin within 30 days after the initial delivery of the depositary shares. Clear-Market We have agreed that, from the date of the underwriting agreement and for a period of 30 days after the date of this prospectus supplement, we will not, without the prior written consent of the representatives, directly or indirectly, issue, offer, sell, offer to sell, or grant any option to sell, pledge, transfer or otherwise dispose of any preferred securities, any preferred stock or any other securities, including any backup undertaking of such preferred stock or other securities, in each case that are substantially similar to the Series B Preferred Stock, or any securities exchangeable for or convertible